New Advances and Current Trends in Bioavailability of Coffee and Coffee By-Product Constituents and Their Metabolites: A Review
- 1VDF FutureCeuticals, Inc., Momence, IL 60954, USA
- 2228 ER Madigan Laboratory, Department of Food Science and Human Nutrition, University of Illinois, Urbana-Champaign, 1201 W. Gregory Dr., Urbana, IL 61801, USA
Abstract
Coffee is one of the most widely consumed beverages worldwide, yet understanding how its bioactive compounds are absorbed and exert health effects remains incomplete. The objective and scope of this review is to critically summarize current advances in coffee bioavailability research, identify major limitations, and highlight emerging research trends. Recent research has advanced in three core areas. First, genetic stratification has moved the field beyond one-size-fits-all approaches by genotyping for key polymorphisms to explain inter-individual variability. Second, advanced metabolomics, including targeted and untargeted LC-MS/MS and multi-omics integration, has provided comprehensive views of phenolic absorption and bioavailability. Third, rigorous intervention designs, including randomized crossover trials and large prospective cohorts with detailed exposure assessment, have improved causal inference. Despite these advances, major limitations persist. Many studies lack sufficient statistical power to detect gene-treatment interactions. The clinical relevance of discovered metabolites is often not established. Observational cohorts remain susceptible to residual confounding, and the field lacks a standardized food matrix for cross-study comparisons. Key strategies to improve the bioavailability of coffee and its by-products were proposed, including novel delivery systems for coffee phytochemicals, human clinical trials involving encapsulated coffee bioactive compounds, and exploring coffee by-products as novel bioactive sources.
Related
- Therapeutic Advances in Mycobacterium avium Complex Pulmonary Disease: Current Treatments and Emerging Host-Directed Approaches
- Nanoencapsulation Strategies for Stabilization and Delivery of Beetroot (Beta vulgaris) Bioactive Compounds: Current Advances and Future Perspectives
- Reconsidering Mineral Formulations in Human Health and Disease: Molecular Mechanisms, Bioavailability and Metabolic Fates
- Cyanobacteria in sustainable agriculture: from bioactive metabolites toward mechanistically validated biostimulants
- Role of 12/15-lipoxygenase and its metabolites in cardiovascular diseases
BibTeX
@article{nemzer2026advances,
title = {{New Advances and Current Trends in Bioavailability of Coffee and Coffee By-Product Constituents and Their Metabolites: A Review}},
author = {Boris Nemzer and Fadwa Al-Taher and Nebiyu Abshiru and Elvira de Mejia},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = nov,
doi = {10.3390/ijms27219841},
url = {https://www.mdpi.com/1422-0067/27/21/9841},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - New Advances and Current Trends in Bioavailability of Coffee and Coffee By-Product Constituents and Their Metabolites: A Review
AU - Boris Nemzer
AU - Fadwa Al-Taher
AU - Nebiyu Abshiru
AU - Elvira de Mejia
PY - 2026
DA - 2026/11/03
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219841
UR - https://www.mdpi.com/1422-0067/27/21/9841
AB - Coffee is one of the most widely consumed beverages worldwide, yet understanding how its bioactive compounds are absorbed and exert health effects remains incomplete. The objective and scope of this review is to critically summarize current advances in coffee bioavailability research, identify major limitations, and highlight emerging research trends. Recent research has advanced in three core areas. First, genetic stratification has moved the field beyond one-size-fits-all approaches by genotyping for key polymorphisms to explain inter-individual variability. Second, advanced metabolomics, including targeted and untargeted LC-MS/MS and multi-omics integration, has provided comprehensive views of phenolic absorption and bioavailability. Third, rigorous intervention designs, including randomized crossover trials and large prospective cohorts with detailed exposure assessment, have improved causal inference. Despite these advances, major limitations persist. Many studies lack sufficient statistical power to detect gene-treatment interactions. The clinical relevance of discovered metabolites is often not established. Observational cohorts remain susceptible to residual confounding, and the field lacks a standardized food matrix for cross-study comparisons. Key strategies to improve the bioavailability of coffee and its by-products were proposed, including novel delivery systems for coffee phytochemicals, human clinical trials involving encapsulated coffee bioactive compounds, and exploring coffee by-products as novel bioactive sources.
SN - 1422-0067
ER -